Safety of bevacizumab in patients with malignant gliomas: a systematic review (Q38166676)

30 August 2017

title

Safety of bevacizumab in patients with malignant gliomas: a systematic review (English)

1 reference

30 August 2017

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24281944%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24281944%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24281944%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

E Trevisan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24281944%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

P Gaviani

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24281944%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

A Botturi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24281944%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

E Lamperti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24281944%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

D Beecher

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24281944%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

C Bosa

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24281944%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

A Salmaggi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24281944%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

language of work or name

1 reference

27 November 2013

1 reference

30 August 2017

published in

Neurological Sciences

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24281944%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24281944%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24281944%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

page(s)

83-89

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24281944%20AND%20SRC:MED&resulttype=core&format=json

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

9 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Angiogenesis in malignant glioma--a target for antitumor therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Mechanisms of angiogenesis in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Corticosteroid Use in Patients with Glioblastoma at First or Second Relapse Treated with Bevacizumab in the BRAIN Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

A phase 2 trial of single‐agent bevacizumab given in an every‐3‐week schedule for patients with recurrent high‐grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Safety of anticoagulation use and bevacizumab in patients with glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Bevacizumab and irinotecan for recurrent oligodendroglial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Treatment with bevacizumab plus carboplatin for recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Irradiation and bevacizumab in high-grade glioma retreatment settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Assessing risk of venous thromboembolism in the patient with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Deep vein thrombosis and cancer: survival, recurrence, and anticoagulant choices

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Venous thromboembolism and malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Thromboembolic phenomena in neurosurgical patients operated upon for primary and metastatic brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Epidemiology of venous thromboembolism in 9489 patients with malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Bevacizumab, bleeding, thrombosis, and warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Increased Risk of Serious Hemorrhage with Bevacizumab in Cancer Patients: A Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-013-1583-6

Incidence of venous thromboembolism and its effect on survival among patients with common cancers

21 January 2018

1 reference

12 December 2020

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

1 reference

12 December 2020

Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial

1 reference

12 December 2020

Postoperative venous thromboembolism and brain tumors: Part I. Clinical profile

1 reference

12 December 2020

10.1007/S10072-013-1583-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24281944%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24281944%20AND%20SRC:MED&resulttype=core&format=json